Literature DB >> 15921709

Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew.

Nissar A Darmani1, Bryan A McClanahan, Chung Trinh, Stefania Petrosino, Marta Valenti, Vincenzo Di Marzo.   

Abstract

The chemotherapeutic agent cisplatin may produce emesis via release of several neurotransmitters such as serotonin (5-HT), substance P and/or dopamine as well as production of prostaglandins (PGs). Administration of synthetic 2-arachidonoylglycerol (2-AG) but not of anandamide, which are two putative endocannabinoids, causes vomiting via its downstream metabolites such as arachidonic acid (AA) and PGs in the least shrew (Cryptotis parva). We report here that cisplatin (0, 5, 10 and 20 mg/kg, i.p.) causes dose- and time-dependent increases in brain tissue levels of 2-AG but not anandamide in this vomiting species. Concomitantly, intestinal tissue levels of both endocannabinoids are relatively reduced. Selective inhibitors [arachidonoyl-serotonin (AA-5-HT) and URB597, 0-5 and 0-10 mg/kg, i.p.] of one of the major endocannabinoid metabolic enzymes, the intracellular fatty acid amide hydrolase (FAAH), do not significantly prevent vomiting produced by emetic doses of i.p.-administered 2-AG, cisplatin or the dopamine receptor agonist apomorphine. At large doses (10 and 20 mg/kg, respectively), both FAAH inhibitors caused emesis per se. Administration of one selective uptake inhibitor of endocannabinoids, OMDM1 (0-5 mg/kg, i.p.), also did not significantly prevent emesis by the direct and indirect emetic stimuli, and likewise caused emesis by itself at a high (10 mg/kg) dose. However, another selective uptake inhibitor, VDM11, did not produce significant emesis per se and prevented emesis caused by apomorphine. Both the corticosteroid dexamethasone, and the cyclooxygenase inhibitor indomethacin, reduced vomiting produced by cisplatin. These data: (a) provide the first evidence that cisplatin causes a selective increase in 2-AG levels in the brain, and (b) support the established notion that 2-AG may produce some of its effects, including emesis, via downstream metabolites produced independently of FAAH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15921709     DOI: 10.1016/j.neuropharm.2005.04.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

1.  Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat.

Authors:  Shelley K Cross-Mellor; Klaus-Peter Ossenkopp; Daniele Piomelli; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2006-11-17       Impact factor: 4.530

2.  Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice.

Authors:  M Bashashati; M A Storr; S P Nikas; J T Wood; G Godlewski; J Liu; W Ho; C M Keenan; H Zhang; S O Alapafuja; B F Cravatt; B Lutz; K Mackie; G Kunos; K D Patel; A Makriyannis; J S Davison; K A Sharkey
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Regulation of nausea and vomiting by cannabinoids.

Authors:  Linda A Parker; Erin M Rock; Cheryl L Limebeer
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew).

Authors:  L A Parker; C L Limebeer; E M Rock; D L Litt; M Kwiatkowska; D Piomelli
Journal:  Physiol Behav       Date:  2009-02-23

5.  Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system.

Authors:  Cheryl L Limebeer; Rehab A Abdullah; Erin M Rock; Elizabeth Imhof; Kai Wang; Aron H Lichtman; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2013-09-17       Impact factor: 4.530

Review 6.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

7.  Receptor-selective agonists induce emesis and Fos expression in the brain and enteric nervous system of the least shrew (Cryptotis parva).

Authors:  Andrew P Ray; Seetha Chebolu; Nissar A Darmani
Journal:  Pharmacol Biochem Behav       Date:  2009-08-21       Impact factor: 3.533

8.  Food restriction, refeeding, and gastric fill fail to affect emesis in musk shrews.

Authors:  Charles C Horn; Liz Still; Christiana Fitzgerald; Mark I Friedman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-05       Impact factor: 4.052

9.  The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew.

Authors:  Yaozhi Wang; Andrew P Ray; Bryan A McClanahan; Nissar A Darmani
Journal:  Pharmacol Biochem Behav       Date:  2008-08-09       Impact factor: 3.533

10.  Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew.

Authors:  Andrew P Ray; Lisa Griggs; Nissar A Darmani
Journal:  Behav Brain Res       Date:  2008-07-31       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.